These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma. Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV Cells; 2022 Feb; 11(4):. PubMed ID: 35203244 [TBL] [Abstract][Full Text] [Related]
7. A mouse model for the Sézary syndrome. Doebbeling U J Exp Clin Cancer Res; 2010 Feb; 29(1):11. PubMed ID: 20149229 [TBL] [Abstract][Full Text] [Related]
8. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. Yano H; Ishida T; Inagaki A; Ishii T; Ding J; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R Clin Cancer Res; 2007 Nov; 13(21):6494-500. PubMed ID: 17975162 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome. van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192 [TBL] [Abstract][Full Text] [Related]
10. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome. Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763 [TBL] [Abstract][Full Text] [Related]
11. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. Yoo EK; Cassin M; Lessin SR; Rook AH J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181 [TBL] [Abstract][Full Text] [Related]
13. [New developments in Sézary syndrome]. Caudron A; Marie-Cardine A; Bensussan A; Bagot M Ann Dermatol Venereol; 2012 Jan; 139(1):31-40. PubMed ID: 22225740 [TBL] [Abstract][Full Text] [Related]
14. Imbalanced IL-1B and IL-18 Expression in Sézary Syndrome. Manfrere KCG; Torrealba MP; Ferreira FM; de Sousa ESA; Miyashiro D; Teixeira FME; Custódio RWA; Nakaya HI; Ramos YAL; Sotto MN; Woetmann A; Ødum N; Duarte AJDS; Sanches JA; Sato MN Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902104 [TBL] [Abstract][Full Text] [Related]
15. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab. Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S Front Immunol; 2020; 11():579894. PubMed ID: 33072126 [TBL] [Abstract][Full Text] [Related]
16. NOTCH1 signaling as a therapeutic target in Sézary syndrome. van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117 [TBL] [Abstract][Full Text] [Related]